Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in chemotherapy-naïve metastatic prostate cancer
NCT01212991Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2010
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Started Sep 2010; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01212991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01212991.